Invesco Biotechnology & Genome ETF
PBE
86 hedge funds and large institutions have $121M invested in Invesco Biotechnology & Genome ETF in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 35 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
5% more funds holding
Funds holding: 82 → 86 (+4)
1.44% less ownership
Funds ownership: 30.87% → 29.43% (-1.4%)
9% less capital invested
Capital invested by funds: $133M → $121M (-$12M)
46% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 35
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$4.38M |
| 2 |
CFS
Commonwealth Financial Services
Vienna,
West Virginia
|
+$593K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$451K |
| 4 |
VF
Virtu Financial
New York
|
+$292K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$228K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$4.95M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.77M |
| 3 |
Morgan Stanley
New York
|
-$4.33M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$3.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.75M |
PBE Hedge Fund Activity: Q4 2015 in Review
86 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2015, worth a combined $121M — down 9% from $133M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PBE positions and 10 closed out — a net gain of 4 holders — while 19 added to existing stakes and 35 trimmed.
The largest buyer was LPL Financial, adding an estimated $4.38M. The largest seller was Freedom Investment Management, exiting entirely with an estimated $4.95M sold.
- 86 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2015, up from 82 in Q3 2015.
- Funds reported $121M of Invesco Biotechnology & Genome ETF stock for Q4 2015, down 9% quarter-over-quarter.
- 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2015 and 10 closed out, a net change of +4 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2015 was LPL Financial, an estimated $4.38M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2015 was Freedom Investment Management, an estimated $4.95M sold.
Based on aggregated 13F filings for Q4 2015.